Author(s): David J. Kuter, M.D., Merlin Efraim, M.D., Jiri Mayer, M.D., Marek Trněný, M.D., Vickie McDonald, M.D., Robert Bird, M.B., B.S., Thomas Regenbogen, M.D., Mamta Garg, M.D., Zane Kaplan, M.D., Nikolay Tzvetkov, M.D., Philip Y. Choi, M.D., A.J. Gerard Jansen, M.D., Milan Kostal, M.D., Ross Baker, M.D., Jaromir Gumulec, M.D., Eun-Ju Lee, M.D., Ilona Cunningham, M.D., Isaac Goncalves, M.D., Margaret Warner, M.D., Ralph Boccia, M.D., Terry Gernsheimer, M.D., Waleed Ghanima, M.D., Olga Bandman, M.D., Regan Burns, B.A., Ann Neale, B.S., Dolca Thomas, M.D., Puneet Arora, M.D., Beiyao Zheng, Ph.D., and Nichola Cooper, M.D.
Author Affiliations
From the Hematology Division, Massachusetts General Hospital, and Harvard Medical School — both in Boston (D.J.K.); the Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna (M.E.), and the Clinic of Hematology, University Multiprofile Hospital for Active Treatment “Dr. Georgi Stranski” EAD, Pleven (N.T.) — both in Bulgaria; the Department of Internal Medicine, Hematology, and Oncology, Masaryk University Hospital, Brno (J.M.), the First Department of Medicine and the Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague (M.T.), the Fourth Department of Internal Medicine and Hematology, Faculty of Medicine, University Hospital of Hradec Kralove, Hradec Kralove (M.K.), and the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava, Ostrava (J.G.) — all in the Czech Republic; Barts Health NHS Trust, the Royal London Hospital (V.M.), and the Department of Immunology and Inflammation, Imperial College London (N.C.), London, and Leicester Royal Infirmary, Leicester (M.G.) — all in the United Kingdom; Princess Alexandra Hospital, Woolloongabba, QLD (R. Bird), Monash Medical Centre, Clayton, VIC (Z.K.), Canberra Hospital, Garran, ACT (P.Y.C.), Perth Blood Institute, Murdoch University, Perth, WA (R. Baker), Concord Repatriation General Hospital, Concord, NSW (I.C.), and Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, VIC (I.G.) — all in Australia; MidMichigan Health, Midland, MI (T.R.); Erasmus MC–University Medical Center, Rotterdam, the Netherlands (A.J.G.J.); NewYork–Presbyterian Hospital and Weill Cornell Medical Center, New York (E.-J.L.); McGill University Health Centre, Montreal (M.W.); the Center for Cancer and Blood Disorders, Bethesda, MD (R. Boccia); the University of Washington Medical Center, Seattle (T.G.); Ostfold Hospital Foundation, Gralum, and the Institute of Clinical Medicine, University of Oslo, Oslo — both in Norway (W.G.); and Principia Biopharma (a Sanofi company), South San Francisco, CA (O.B., R. Burns, A.N., D.T., P.A., B.Z.).
1 thought on “Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia”
Hi Lucio,
Interesting there were no cases of bleeding. Is platelet dysfunction a class toxicity with BTK’s? Perhaps it’s less likely with the second-generation drugs.
Kind regards,
Mark Moskowitz